1. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue at least one haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator for a time sufficient to join or approximate said wounded tissue andor to reduce the flow of fluid from said wounded tissue, wherein said haemostatic material is substantially homogeneous.
2. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue at least one haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator for a time sufficient to join or approximate said wounded tissue andor to reduce the flow of fluid from said wounded tissue, wherein said haemostatic material is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator.
3. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue at least one haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator for a time sufficient to join or approximate said wounded tissue andor to reduce the flow of fluid from said wounded tissue, wherein said haemostatic material is cast or formed as a single piece.
4. (canceled)
5. The method of claim 4, wherein said support layer comprises a backing material.
6. The method of claim 4, wherein said support layer comprises an internal support material.
7. The method of claim 4, wherein said support layer comprises a resorbable material.
8. The method of claim 4, wherein said support layer comprises a non-resorbable material.
9. The method of claim 8, wherein said non-resorbable material is selected from the group consisting of silicone polymers, paper, gauze, plastics, non-resorbable suture materials, latexes and suitable derivatives of thereof.
10. The method of claim 4, further comprising at least one physiologically acceptable adhesive between said haemostatic material and said backing layer.
11. The method of claim 7, wherein said resorbable material is selected from the group consisting of proteinaceous materials, carbohydrate substances and resorbable suture materials.
12. The method of claim 11, wherein said proteinaceous material is at least one substance selected from the group consisting of keratin, silk, fibrin, collagen, gelatin and suitable derivatives thereof.
13. The method of claim 11, wherein said carbohydrate substance is selected from the group consisting of alginic acid and salts thereof, chitin, chitosan, cellulose, n-acetyl glucosamine, proteoglycans, glycolic acid polymers, lactic acid polymers, glycolic acidlactic acid co-polymers, suitable derivatives thereof and mixtures of two or more thereof.
14. (canceled)
15. (canceled)
16. The method of claim 15, wherein said filler is selected from the group consisting of sucrose, lactose, maltose, keratin, silk, fibrin, collagen, gelatin, albumin, polysorbate, chitin, chitosan., alginic acid and salts thereof, cellulose, proteoglycans, glycolic acid polymers, lactic acid polymers, glycolic acidlactic acid co-polymers, and mixtures of two or more thereof.
17. The method of claim 15, wherein said solubilizing agent is selected from the group consisting of sucrose, lactose, maltose, dextrose, mannose, trehalose, mannitol, sorbitol, albumin, sorbate, polysorbate, and mixtures of two or more thereof.
18. The method of claim 15, wherein said release agent is selected from the group consisting of gelatin, mannitol, sorbitol, polysorbate, sorbitan, lactose, maltose, trehalose, sorbate, glucose and mixtures of two or more thereof.
19. The method of claim 15, wherein said foaming agent is selected from the group consisting of mixtures of sodium bicarbonatecitric acid, sodium bicarbonateacetic acid, calcium carbonatecitric acid and calcium carbonateacetic acid.
20. (canceled)
21. The method of claim 20, wherein said therapeutic supplement is present in an amount equal to or greater than its solubility limit in fibrin.
22. The method of claim 4, wherein said haemostatic material further contains at least one binding agent in an amount effective to retain the physical integrity of said haemostatic material.
23. The method of claim 22, wherein said binding agent is selected from the group consisting of sucrose, mannitol, sorbitol, gelatin, maltose, povidone, chitosan, carboxymethylcellulose and derivatives thereof.
24. (canceled)
25. (canceled)
26. (canceled)
27. (canceled)
28. (canceled)
29. (canceled)
30. The method of claim 29, wherein said mammalian fibrinogen is selected from the group consisting of bovine fibrinogen, porcine fibrinogen, ovine fibrinogen, equine fibrinogen, caprine fibrinogen, feline fibrinogen, canine fibrinogen, murine fibrinogen and human fibrinogen.
31. (canceled)
32. (canceled)
33. The method of claim 29, wherein said mammalian fibrinogen is selected from the group consisting of recombinantly produced fibrinogen and transgenic fibrinogen.
34. (canceled)
35. The method of claim 34, wherein said thrombin is mammalian thrombin.
36. The method of claim 35, wherein said mammalian thrombin is selected from the group consisting of bovine thrombin, porcine thrombin, ovine thrombin, equine thrombin, caprine thrombin, feline thrombin, canine thrombin, murine thrombin and human thrombin.
37. The method of claim 34, wherein said thrombin is selected from the group consisting of bird thrombin and fish thrombin.
38. (canceled)
39. (canceled)
40. The method of claim 39, wherein said method is performed as a part of vascular access sealing and said haemostatic material is applied as a disk or pellet using a guide wire.
41. A haemostatic material consisting essentially of a mixture of fibrinogen component, a fibrinogen activator and water, wherein said mixture is frozen and is stable at a temperature of less than 0\xb0 C. for at least 24 hours.
42. The haemostatic material of claim 41, wherein said mixture also contains one or more of the following: at least one binding agent, at least one filler; at least one solubilizing agent; at least one foaming agent; and at least one release agent.
43. The haemostatic material of claim 41, wherein said mixture also contains at least one therapeutic supplement selected from the group consisting of antibiotics, anticoagulants, steroids, cardiovascular drugs, growth factors, antibodies (poly and mono), chemoattractants, anesthetics, antiproliferativesantitumor agents, antivirals, cytokines, colony stimulating factors, antifungals, antiparasitics, antiinflammatories, antiseptics, hormones, vitamins, glycoproteins, fibronectin, peptides, proteins, carbohydrates, proteoglycans, antiangiogenins, antigens, nucleotides, lipids, liposomes, fibrinolysis inhibitors, procoagulants, anticoagulants, vascular constrictors and gene therapy reagents.
44. The haemostatic material of claim 41, wherein said mixture also contains at least one support material.
The claims below are in addition to those above.
All refrences to claims which appear below refer to the numbering after this setence.
1. A latch assembly for doors, seats, or seatbacks of motor vehicles, comprising:
a lock housing;
a latch element installed rotatably in the lock housing to retain an opposing latch part when the assembly is in a locking position, the opposing latch part being disconnectable from the latch element when the assembly is in a released position; and
a tensioning member, which, when the assembly is in the locking position, exerts a tensioning force by which a tension edge forming a permanent part of the opposing latch part is pressed against an opposing tension edge forming a permanent part of the lock housing, wherein the tensioning member is a slide plate supported on a guide edge of the lock housing so that when the tensioning member shifts from a tensioning position to a release position the slide plate slides along the guide edge, which forms a permanent part of the lock housing, at least a certain area of the slide plate forming a tensioning cam that is at an angle relative to movement of the slide plate and cooperates with a projection on the latch element, further comprising a stop pawl having a stop hook that extends under a stop edge of the latch element when the assembly is in the locking position, and an opening lever having a first arm that, when subjected to an opening force, acts on an extension of the tensioning member to move the tensioning member into a released position, in which the projection can enter the escape space, wherein the opening lever has a second arm, which, when subjected to an opening force, acts on a driver on the stop pawl to move the stop pawl into a released position, in which the stop hook does not extend under the stop edge.
2. The latch assembly according to claim 1, wherein the slide plate slides in a direction parallel to a direction in which the opposing latch part is captured.
3. The latch assembly according to claim 2, the tensioning cam is a boundary edge of a window in the tensioning member, which window forms an escape space following after the cam, into which space the projection lies when the assembly is in the released position.
4. The latch assembly according to claim 2, wherein the tensioning member comprises a slot, in which a guide projection coaxial to a pivot axis of the latch element engages.
5. The latch assembly according to claim 4, wherein the guide projection is a hub of a rotary latch forming the latch element, the hub having a diameter equal to a width of the slot in the tensioning member.
6. The latch assembly according to claim 2, further comprising a tension spring that acts on a spring support forming a permanent part of the lock housing and on the tensioning member to produce a tensioning force.
7. The latch assembly according to claim 2, wherein the tension edge is assigned to a latch member carrier, and the opposing tension edge is an outside edge of the lock housing.
8. A latch assembly for doors, seats, or seatbacks of motor vehicles, comprising:
a lock housing;
a latch element installed rotatably in the lock housing to retain an opposing latch part when the assembly is in a locking position, the opposing part being disconnectable from the latch element when the assembly is in a released position; and
a tensioning member, which, when the assembly is in the locking position, exerts a tensioning force by which a tension edge forming a permanent part of the opposing latch part is pressed against an opposing tension edge forming a permanent part of the lock housing, wherein at least a certain section of the tension edge is a substantially straight wall of a latch member carrier, and the opposing tension edge is a wall of the lock housing extending parallel to the tension edge, wherein the tensioning member is a slide plate supported on a guide edge that is a permanent part of the lock housing and is slideable along the guide edge when the tensioning member shifts from the locking position to a released position, the slide plate having a tensioning cam that cooperates with a projection on the latch element, further comprising a stop pawl having a stop hook that extends under a stop edge of the latch element when the assembly is in the locking position, and an opening lever having a first arm that, when subjected to an opening force, acts on an extension of the tensioning member to move the tensioning member into a released position, in which the projection can enter the escape space, wherein the opening lever has a second arm, which, when subjected to an opening force, acts on a driver on the stop pawl to move the stop pawl into a released position, in which the stop hook does not extend under the stop edge.